Chardan Capital reaffirmed their buy rating on shares of Silence Therapeutics (NASDAQ:SLN – Free Report) in a research note issued to investors on Friday, Benzinga reports. The firm currently has a $42.00 price target on the stock. A number of other analysts have also commented on SLN. BMO Capital Markets initiated coverage on Silence Therapeutics […]
Shares of Cullinan Oncology, Inc. (NASDAQ:CGEM – Get Free Report) have been given a consensus rating of “Buy” by the seven ratings firms that are presently covering the company, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokers that have issued a report […]
Shares of Sutro Biopharma, Inc. (NASDAQ:STRO – Get Free Report) have earned an average rating of “Buy” from the eight ratings firms that are covering the firm, Marketbeat reports. Eight equities research analysts have rated the stock with a buy rating. The average twelve-month price target among analysts that have updated their coverage on the […]
Cullinan Oncology, Inc. (NASDAQ:CGEM – Get Free Report) has been given an average rating of “Buy” by the seven ratings firms that are covering the stock, MarketBeat reports. Seven analysts have rated the stock with a buy rating. The average 12 month target price among brokerages that have covered the stock in the last year […]
Akoya Biosciences, Inc. (NASDAQ:AKYA – Free Report) – Capital One Financial lowered their Q2 2024 EPS estimates for shares of Akoya Biosciences in a research note issued on Monday, May 13th. Capital One Financial analyst T. Chiang now expects that the company will earn ($0.28) per share for the quarter, down from their prior estimate […]